MEI Pharma, Inc.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) securities during the period from August 2, 2017 through July 1, 2020 inclusive (the "Class Period"). Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the Complaint, the Company made false and misleading statements to the market. MEI Pharma overstated the potential efficacy of its drug Pracinostat as treatment for acute myeloid leukemia ("AML") in its target population. Pracinostat's Phase 3 Trial was, therefore, unlikely to meet its primary endpoint on overall survival. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about MEI Pharma, investors suffered damages.
If you acquired MEI Pharma securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at firstname.lastname@example.org, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.